Cancer Cell-Derived PDGFB Stimulates mTORC1 Activation in Renal Carcinoma

Int J Mol Sci. 2023 Mar 29;24(7):6447. doi: 10.3390/ijms24076447.

Abstract

Clear cell renal cell carcinoma (ccRCC) is a hypervascular tumor that is characterized by bi-allelic inactivation of the VHL tumor suppressor gene and mTOR signalling pathway hyperactivation. The pro-angiogenic factor PDGFB, a transcriptional target of super enhancer-driven KLF6, can activate the mTORC1 signalling pathway in ccRCC. However, the detailed mechanisms of PDGFB-mediated mTORC1 activation in ccRCC have remained elusive. Here, we investigated whether ccRCC cells are able to secrete PDGFB into the extracellular milieu and stimulate mTORC1 signalling activity. We found that ccRCC cells secreted PDGFB extracellularly, and by utilizing KLF6- and PDGFB-engineered ccRCC cells, we showed that the level of PDGFB secretion was positively correlated with the expression of intracellular KLF6 and PDGFB. Moreover, the reintroduction of either KLF6 or PDGFB was able to sustain mTORC1 signalling activity in KLF6-targeted ccRCC cells. We further demonstrated that conditioned media of PDGFB-overexpressing ccRCC cells was able to re-activate mTORC1 activity in KLF6-targeted cells. In conclusion, cancer cell-derived PDGFB can mediate mTORC1 signalling pathway activation in ccRCC, further consolidating the link between the KLF6-PDGFB axis and the mTORC1 signalling pathway activity in ccRCC.

Keywords: CRISPR/Cas9; KLF6; PDGFB; mTOR signalling pathway; renal cancer.

MeSH terms

  • Becaplermin / metabolism
  • Carcinoma, Renal Cell* / pathology
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Kidney Neoplasms* / metabolism
  • Mechanistic Target of Rapamycin Complex 1 / metabolism
  • Proto-Oncogene Proteins c-sis / metabolism
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics

Substances

  • Proto-Oncogene Proteins c-sis
  • Mechanistic Target of Rapamycin Complex 1
  • Becaplermin
  • Von Hippel-Lindau Tumor Suppressor Protein